From: Alleviating neurodegeneration in Drosophila models of PolyQ diseases
Therapeutic strategy | Functional mechanism | Drosophila model | Therapeutic result | Reference |
---|---|---|---|---|
RNAi | Inhibiting formation of polyQ-expanded protein | SCA1, SCA3, HD | Positive | Mallik et al. [50] |
Cystamine | reducing Huntingtin (Htt) aggregation | HD | Positive | Apostol et al. [51] |
Agrawal et al. [52] | ||||
Bortvedt et al. [53] | ||||
Methylene blue (MB) | Inhibiting Htt aggregation | HD | Positive | Sontag et al [54] |
18b-glycyrrhetinic acid | Inhibiting Htt aggregation | HD | Positive | Schulte et al. [55] |
Camptothecins | Inhibiting Htt aggregation | HD | Positive | Schulte et al. [55] |
OH-camptothecin | Inhibiting Htt aggregation | HD | Positive | Schulte et al. [55] |
Carbenoxolone | Inhibiting Htt aggregation | HD | Positive | Schulte et al. [55] |
Polyglutamine binding peptide 1 (QBP1) | Inhibiting polyQ aggregation | SCA3/MJD | Positive | Nagai et al. [56] |
P42 | Inhibiting polyQ-hHtt aggregation | HD | Positive | Arribat et al. [57] |
Hsp70 | Reversing toxic structure of polyQ-expanded proteins | SCA3/MJD, SBMA | Positive | Warrick et al [58] |
Wang et al [59] | ||||
Hsp40 | Reversing toxic structure of polyQ-expanded proteins | HD | Positive | Kazemi et al [49] |
Kuo et al. [60] | ||||
Hsp110 | Reversing toxic structure of polyQ-expanded proteins | HD | Positive | Kuo et al. [60] |
Hsp22 | Reversing toxic structure of polyQ-expanded proteins | SCA3/MJD | Positive | Li et al. [61] |
Rapamycin | Accelerating toxic proteins degradation | HD | Positive but various side-effects on human | Ravikumar et al. [62] |
Morrisett et al. [63] | ||||
Letavernier et al. [64] | ||||
Kuypers et al. [65] | ||||
Maroto et al. [66] | ||||
Lithium chloride (LiCl) | Accelerating toxic proteins degradation | SCA3/MJD | Positive | Jia et al. [67] |
Normal ataxin-3 | Accelerating toxic proteins degradation | SCA3/MJD | Positive | Warrick et al. [68] |
Hsp104 | Accelerating toxic proteins degradation | SCA3/MJD | Positive | Cushman et al. [69] |
Sodium butyrate | Transcriptional regulation | HD | Positive | Steffan et al. [70] |
Suberoylanilide hydroxamic acid (SAHA) | Transcriptional regulation | HD | Positive | Steffan et al. [70] |
Trichostatin A (TSA) | Transcriptional regulation | SCA3/MJD | Positive | Jung et al. [71] |
Valproic acid (VPA) | Transcriptional regulation | SCA3/MJD | Positive | Yi et al. [72] |
Myc | Transcriptional regulation | SCA3/MJD | Positive | Singh et al. [73] |
Uncoupling proteins (UCPs) | Ameliorating mitochondrial dysfunctions | HD | Positive | Besson et al. [74] |
Meclizine | Ameliorating mitochondrial dysfunctions | HD | Positive | Gohil et al. [75] |